Atrial fibrillation, liver disease, antithrombotics and risk of cerebrovascular events: A population-based cohort study

International Journal of Cardiology

Volumn 223, Issue , 2016, Pages 829-837

  Lai, Hui Chin ^a,b   Chien, Wu Chien ^c   Chung, Chi Hsiang ^d   Lee, Wen Lieng ^a,b   Wu, Tsu Juey ^a,b   Wang, Kuo Yang ^a,e   Liu, Chia Ning ^b   Liu, Tsun Jui ^a,b,f  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIWANESE INJURY PREVENTION AND SAFETY PROMOTION ASSOCIATION   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antithrombotic; Atrial fibrillation; Cerebrovascular; CHA2DS2 VASc; Liver; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHA2DS VASC SCORE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; VULNERABLE POPULATION; CEREBROVASCULAR DISORDERS; HEALTH SURVEY; LIVER DISEASES; LONGITUDINAL STUDY; MIDDLE AGED; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CEREBROVASCULAR DISORDERS; COHORT STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIVER DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; TAIWAN;

EID: 84983548906     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.08.297     Document Type: Article

References (39)

1. [1] Patel, N.J., Deshmukh, A., Pant, S., et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 129 (2014), 2371–2379.
2. [2] Cairns, J.A., Connolly, S.J., Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 84 (1991), 469–481.
3. [3] Lai, H.C., Chien, W.C., Chung, C.H., et al. Atrial fibrillation, cha2ds2-vasc score, antithrombotics and risk of traffic accidents: a population-based cohort study. Int. J. Cardiol. 197 (2015), 133–139.
4. [4] Lai, H.C., Chien, W.C., Chung, C.H., et al. Atrial fibrillation, cha2ds2-vasc score, antithrombotics and risk of non-traffic-, non-cancer-related bone fractures: a population-based cohort study. Eur. J. Intern. Med., 2015.
5. [5] Lai, H.C., Chien, W.C., Chung, C.H., et al. Atrial fibrillation increases medical cost and complicates hospital outcome of traffic accident-related physical trauma—a nationwide population-based study. Int. J. Cardiol. 177 (2014), 964–969.
6. [6] January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 64 (2014), e1–76.
7. [7] Wang, Y., Bajorek, B., Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther. Adv. Drug Saf. 5 (2014), 21–37.
8. [8] Basili, S., Raparelli, V., Violi, F., The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? Yes. Eur. J. Intern. Med. 21 (2010), 62–64.
9. [9] Tripodi, A., Mannucci, P.M., The coagulopathy of chronic liver disease. N. Engl. J. Med. 365 (2011), 147–156.
10. [10] Northup, P.G., Hypercoagulation in liver disease. Clin. Liver Dis. 13 (2009), 109–116.
11. [11] Northup, P.G., Argo, C.K., Shah, N., et al. Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin. Liver Dis. 32 (2012), 39–48.
12. [12] Northup, P.G., Sundaram, V., Fallon, M.B., et al. Hypercoagulation and thrombophilia in liver disease. J. Thromb. Haemost. 6 (2008), 2–9.
13. [13] Targher, G., Chonchol, M., Miele, L., et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin. Thromb. Hemost. 35 (2009), 277–287.
14. [14] Chen, C.Y., Lee, K.T., Lee, C.T., et al. Effectiveness and safety of antiplatelet therapy in stroke recurrence prevention in patients with liver cirrhosis: a 2-year follow-up study. Pharmacoepidemiol. Drug Saf. 21 (2012), 1334–1343.
15. [15] Plompen, E.P., Schouten, J.N., Janssen, H.L., Role of anticoagulant therapy in liver disease. Hepatol. Int. 7 (2013), 369–376.
16. [16] Cheng, C.L., Kao, Y.H., Lin, S.J., et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol. Drug Saf. 20 (2011), 236–242.
17. [17] Macle, L., Cairns, J.A., Andrade, J.G., et al. The 2014 atrial fibrillation guidelines companion: a practical approach to the use of the Canadian Cardiovascular Society guidelines. Can. J. Cardiol. 31 (2015), 1207–1218.
18. [18] De Feo, P., Lucidi, P., Liver protein synthesis in physiology and in disease states. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002), 47–50.
19. [19] Ritland, S., Skrede, S., Blomhoff, J.P., et al. Coagulation factors as indicators of protein synthesis in chronic liver disease. Scand. J. Gastroenterol. Suppl. 19 (1973), 113–117.
20. [20] Muszkat, M., Blotnik, S., Elami, A., et al. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of cyp2c9 genetic polymorphism in the presence of drug-disease and drug–drug interactions. Clin. Ther. 29 (2007), 427–437.
21. [21] Zocco, M.A., Di Stasio, E., De Cristofaro, R., et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with Meld scoring system and portal vein thrombosis development. J. Hepatol. 51 (2009), 682–689.
22. [22] Targher, G., Valbusa, F., Bonapace, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One, 8, 2013, e57183.
23. [23] Targher, G., Byrne, C.D., Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin. Thromb. Hemost. 39 (2013), 214–228.
24. [24] Dabbagh, O., Oza, A., Prakash, S., et al. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest 137 (2010), 1145–1149.
25. [25] Davenport, A., Ultrafiltration in diuretic-resistant volume overload in nephrotic syndrome and patients with ascites due to chronic liver disease. Cardiology 96 (2001), 190–195.
26. [26] Alonso, A., Misialek, J.R., Amiin, M.A., et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the atherosclerosis risk in communities cohort. Heart 100 (2014), 1511–1516.
27. [27] Yuri, T., Kato, K., Hirohara, Y., et al. Trousseau's syndrome caused by intrahepatic cholangiocarcinoma: an autopsy case report and literature review. Case Rep. Oncol. 7 (2014), 376–382.
28. [28] Ichida, F., Shibazaki, K., Toeda, K., Paraneoplastic syndrome—primary liver tumor. Nihon Rinsho Jpn. J. Clin. Med. 35:Suppl. 1 (1977), 906–907.
29. [29] Bick, R.L., Coagulation abnormalities in malignancy: a review. Semin. Thromb. Hemost. 18 (1992), 353–372.
30. [30] Lip, G.Y., Frison, L., Halperin, J.L., et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J. Am. Coll. Cardiol. 57 (2011), 173–180.
31. [31] Lip, G.Y., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
32. [32] Lee, S.J., Uhm, J.S., Kim, J.Y., et al. The safety and efficacy of vitamin k antagonist in patients with atrial fibrillation and liver cirrhosis. Int. J. Cardiol. 180 (2015), 185–191.
33. [33] Papatheodoridis, G.V., Papakonstantinou, E., Andrioti, E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52 (2003), 404–409.
34. [34] Dammacco, F., Vacca, A., Procaccio, P., et al. Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin. Exp. Med. 13 (2013), 85–97.
35. [35] Walsh-McMonagle, D., Green, D., Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 80 (1997), 649–655.
36. [36] Chen, D.S., Hepatitis c virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 25 (1995), 27–32.
37. [37] Chen, D.S., Sung, J.L., Hepatitis b virus infection and chronic liver disease in Taiwan. Acta Hepatogastroenterol. 25 (1978), 423–430.
38. [38] Hsu, C.S., Kao, J.H., Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan. J. Formos. Med. Assoc. 111 (2012), 527–535.
39. [39] Hoteit, M.A., Ghazale, A.H., Bain, A.J., et al. Model for end-stage liver disease score versus child score in predicting the outcome of surgical procedures in patients with cirrhosis. World J. Gastroenterol. 14 (2008), 1774–1780.